Filing Analysis
vTv Therapeutics Inc. announced its financial results for the first quarter ended March 31, 2026. The filing serves as a formal notice of the earnings release and includes the associated press release as an exhibit.
📋 Key Facts
- Announced financial results for the quarter ended March 31, 2026.
- Filed under Item 2.02 (Results of Operations and Financial Condition).
- Included Exhibit 99.1, the press release detailing the financial results.
- Signed by President and CEO Paul J. Sekhri on May 13, 2026.
vTv Therapeutics Inc. filed a prospectus supplement on May 13, 2026, to increase the number of shares of Class A common stock offered under its existing at-the-market (ATM) sales program. The company is moving to utilize the full amount provided for under the program to facilitate capital raising.
🚩 Red Flags
- Potential for significant shareholder dilution as the company maximizes its ATM issuance
- Frequent reliance on ATM programs in micro-cap biotech often signals a limited cash runway
📋 Key Facts
- Filed prospectus supplement on May 13, 2026
- Increased ATM Program shares to the full amount originally provided for
- Filed a legal opinion from Dechert LLP (Exhibit 5.1) regarding the legality of the shares
- The shares are being issued under an existing shelf Registration Statement on Form S-3
vTv Therapeutics Inc. has updated its investor presentation as of March 10, 2026, for use in upcoming meetings with investors and analysts. The presentation was filed under Regulation FD and is available as Exhibit 99.1.
📋 Key Facts
- Updated investor presentation posted to the company website on March 10, 2026
- The presentation will be used for meetings with analysts and other parties
- The filing is made under Item 7.01 Regulation FD Disclosure
- Exhibit 99.1 contains the full investor presentation dated March 2026
vTv Therapeutics Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release on March 10, 2026.
📋 Key Facts
- The company reported financial results for the fiscal year ended December 31, 2025
- The announcement was made through a press release dated March 10, 2026
- The filing was made under Item 2.02 (Results of Operations and Financial Condition)
vTv Therapeutics Inc. updated its corporate investor presentation on February 26, 2026, for use in upcoming meetings with investors and analysts. The presentation was filed as an exhibit to comply with Regulation FD requirements.
📋 Key Facts
- The company posted an updated slide presentation to its website on February 26, 2026.
- The presentation is intended for use in meetings with investors, analysts, and other parties.
- The filing was made under Item 7.01 (Regulation FD Disclosure) and includes Exhibit 99.1.
- The presentation is dated February 2026.